TechConnect Innovation Program

Novel Systemic Drug Delivery System for Back of the Eye Diseases

Johns Hopkins Technology Ventures, MD, United States

TECHNOLOGY SUMMARY

Johns Hopkins researchers have developed a drug delivery system that selectively targets sites of inflammation. Agents in development include an anti‐inflammatory agent for neuroinflammation and an approved corticosteroid for retinal degeneration.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Concept

Technology Readiness Level: TRL 4

FIGURES OF MERIT

Value Proposition: • Targeted drug delivery to inflammation site activates immune defense at retina and choroid
• Biodegradable hydrogel formulations enable sustained release and multi‐functional or high payload drug delivery
• can overcome blood-brain barrier for high therapeutic efficacy

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Showcase Booth #: 18T

Website: http://ventures.jhu.edu/

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date:

Primary Sources of Funding: Federal Grant, University

Looking for: Both Funding and Development Partners